Literature DB >> 11929709

Dendritic cell subtypes in autoimmune liver diseases; decreased expression of HLA DR and CD123 on type 2 dendritic cells.

Yoichi Hiasa1, Sk Md. Fazie Akbar, Masanori Abe, Kojiro Michitaka, Norio Horiike, Morikazu Onji.   

Abstract

In order to dissect the role of different subsets of antigen-presenting dendritic cell (DC) in autoimmune liver diseases, we analyzed the frequencies and phenotypes of DC1 and DC2 from patients with primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH). The numbers of DC, DC1 and DC2 in a fixed amount of peripheral blood (20 ml) from 14 patients with PBC (therapy [-]: 5, therapy [+]: 9), seven patients with AIH (therapy [-]): 4, therapy [+]: 3), nine patients with chronic hepatitis due to hepatitis C virus and 12 healthy subjects were estimated using three-color flow cytometry. The mean fluorescence intensities of HLA DR, CD11c and CD123 on DC subsets were evaluated from the flow cytometric profiles. The numbers of DC1 and DC2 did not differ significantly among patients and controls. The expression of HLA DR was lower on DC1 from patients with AIH, but not on PBC. However, the levels of HLA DR and CD 123 on DC2 were significantly decreased in patients with PBC (therapy [-]) and AIH (therapy [-]) compared with healthy subjects (P<0.05). Defective phenotype of DC2 in both AIH and PBC may have a relevance to the breakdown of tolerance to self antigen in these autoimmune diseases. Functional study of DC2 in autoimmune liver diseases is warranted.

Entities:  

Year:  2002        PMID: 11929709     DOI: 10.1016/s1386-6346(01)00149-8

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

1.  Periportal and sinusoidal liver dendritic cells suppressing T helper type 1-mediated hepatitis.

Authors:  Tomohiro Watanabe; Hiroaki Katsukura; Tsutomu Chiba; Toru Kita; Yoshio Wakatsuki
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

2.  Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.

Authors:  Ming Shi; Bing Zhang; Zi-Rong Tang; Zhou-Yun Lei; Hui-Fen Wang; Yong-Yi Feng; Zhen-Ping Fan; Dong-Ping Xu; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

3.  FOXO3-dependent apoptosis limits alcohol-induced liver inflammation by promoting infiltrating macrophage differentiation.

Authors:  Zhuan Li; Jie Zhao; Shujun Zhang; Steven A Weinman
Journal:  Cell Death Discov       Date:  2018-02-13

Review 4.  Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.

Authors:  Chang Wang; Ying Shi; Xiaomei Wang; Heming Ma; Quan Liu; Yanhang Gao; Junqi Niu
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

5.  FC-98 regulates TLR9-mediated of CXCL-10 expression in dendritic cells via MAPK and STAT1 signaling pathway.

Authors:  Yonghong Yang; Huan Dou; Xiaoqin Li; Yuxian Song; Wei Gong; Renxiang Tan; Yayi Hou
Journal:  Biomed Res Int       Date:  2014-02-17       Impact factor: 3.411

6.  CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis.

Authors:  Kyoko Tomita; Brittany L Freeman; Steven F Bronk; Nathan K LeBrasseur; Thomas A White; Petra Hirsova; Samar H Ibrahim
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

7.  Single cell sequencing analysis identifies genetics-modulated ORMDL3+ cholangiocytes having higher metabolic effects on primary biliary cholangitis.

Authors:  Bingyu Xiang; Chunyu Deng; Fei Qiu; Jingjing Li; Shanshan Li; Huifang Zhang; Xiuli Lin; Yukuan Huang; Yijun Zhou; Jianzhong Su; Mingqin Lu; Yunlong Ma
Journal:  J Nanobiotechnology       Date:  2021-12-06       Impact factor: 10.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.